Report cover image

Meningococcal Vaccines Market by Type (Combination Vaccines, Conjugate Vaccines, Men B Vaccines), Category (Intramuscular, Subcutaneous), Dosage Type, Target Group, End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 188 Pages
SKU # IRE18445945

Description

Meningococcal Vaccines Market by Type (Combination Vaccines, Conjugate Vaccines, Men B Vaccines), Category (Intramuscular, Subcutaneous), Dosage Type, Target Group, End-User - Global Forecast 2024-2030


The Meningococcal Vaccines Market size was estimated at USD 5.45 billion in 2023 and expected to reach USD 5.95 billion in 2024, at a CAGR 10.50% to reach USD 10.97 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Meningococcal Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Meningococcal Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type

Combination Vaccines
MenHibrix
Menitorix

Conjugate Vaccines
Menactra
MenAfriVac
Meningitec
Menjugate
Menveo
NeisVac-C
Nimenrix
NmVac4-DT

Men B Vaccines
Bexsero
Trumenba

Polysaccharide Vaccines
Mencevax
Menomune
NmVac4
Category

Intramuscular

Subcutaneous
Dosage Type

Booster Vaccination

Primary Vaccination
Target Group

Adult

Preteen

Teenager
End-User

Hospital Pharmacies

Pediatric Clinic

Retail Pharmacies
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Meningococcal Vaccines Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Meningococcal Vaccines Market?
3. What are the technology trends and regulatory frameworks in the Meningococcal Vaccines Market?
4. What is the market share of the leading vendors in the Meningococcal Vaccines Market?
5. Which modes and strategic moves are suitable for entering the Meningococcal Vaccines Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

188 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Meningococcal Vaccines Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of Meningitis Across the World
5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
5.1.2. Restraints
5.1.2.1. High Cost of Meningococcal Vaccines Production
5.1.3. Opportunities
5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
5.1.4. Challenges
5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Meningococcal Vaccines Market, by Type
6.1. Introduction
6.2. Combination Vaccines
6.3.1. MenHibrix
6.3.2. Menitorix
6.3. Conjugate Vaccines
6.4.1. Menactra
6.4.2. MenAfriVac
6.4.3. Meningitec
6.4.4. Menjugate
6.4.5. Menveo
6.4.6. NeisVac-C
6.4.7. Nimenrix
6.4.8. NmVac4-DT
6.4. Men B Vaccines
6.5.1. Bexsero
6.5.2. Trumenba
6.5. Polysaccharide Vaccines
6.6.1. Mencevax
6.6.2. Menomune
6.6.3. NmVac4
7. Meningococcal Vaccines Market, by Category
7.1. Introduction
7.2. Intramuscular
7.3. Subcutaneous
8. Meningococcal Vaccines Market, by Dosage Type
8.1. Introduction
8.2. Booster Vaccination
8.3. Primary Vaccination
9. Meningococcal Vaccines Market, by Target Group
9.1. Introduction
9.2. Adult
9.3. Preteen
9.4. Teenager
10. Meningococcal Vaccines Market, by End-User
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Pediatric Clinic
10.4. Retail Pharmacies
11. Americas Meningococcal Vaccines Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Meningococcal Vaccines Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Meningococcal Vaccines Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Astellas Pharma Inc.
15.1.2. AstraZeneca PLC
15.1.3. Bavarian Nordic A/S
15.1.4. Bharat Biotech Ltd.
15.1.5. Bio-Manguinhos
15.1.6. Bio-Med (P) Limited
15.1.7. CanSino Biologics Inc.
15.1.8. Chongqing Zhifei Biological Products Co., Ltd.
15.1.9. Emergent BioSolutions Inc.
15.1.10. GlaxoSmithKline PLC
15.1.11. Incepta Pharmaceuticals Ltd.
15.1.12. Merck & Co., Inc.
15.1.13. Mitsubishi Tanabe Pharma Corporation
15.1.14. Nanolek, LLC
15.1.15. Novartis AG
15.1.16. Panacea Biotec Ltd.
15.1.17. Petrovax Pharm
15.1.18. Pfizer Inc.
15.1.19. Sanofi S.A.
15.1.20. Serum Institute of India Pvt. Ltd.
15.1.21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
15.1.22. Sinovac Biotech Ltd.
15.1.23. SK bioscience
15.1.24. Taj Pharmaceuticals Limited
15.1.25. Vabiotech
15.1.26. Walvax Biotechnology Co., Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MENINGOCOCCAL VACCINES MARKET DYNAMICS
FIGURE 7. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
FIGURE 10. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2030 (%)
FIGURE 12. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2030 (%)
FIGURE 14. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us